Funding for this research was provided by:
Cancer Research UK (RES/0190/7915, CRUKD/12/004, RES/0190/7915)
Department of Health (RES/0190/7915)
Received: 10 June 2019
Revised: 16 December 2019
Accepted: 8 January 2020
First Online: 20 February 2020
Change Date: 12 March 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-020-0801-2
Ethics approval and consent to participate
: The clinical trial of AZD3965 is ethically approved by the Newcastle and North Tyneside Regional Ethics Committee 1 (REC number 12/NE/0345) and run according to the standards of Good Clinical Practice as set out in the Declaration of Helsinki.
: The patient gave separate informed consent for publication of his case and the associated images.
: There are no raw data published in this paper.
: The authors declare no competing interests.
: The AZD3965 clinical trial is sponsored and funded by the Cancer Research UK Centre for Drug Development. The patient was cared for at the Newcastle Experimental Cancer Medicine Centre, which is jointly funded by the Cancer Research UK and the Department of Health, UK (grant number RES/0190/7915). The urine lactate studies were performed at the Imperial College London Experimental Cancer Medicine Centre under a statement of work funded by CRUK (grant number CRUKD/12/004). Immunohistochemistry was performed in the MRC/EPSRC Newcastle Molecular Pathology Node under a Specialist Unit Agreement with CRUK.